Incyte (INCY) has reported 1Q20 EPS that included a 22% year-over-year rise in blood cancer drug Jakafi to $460 million, above consensus of …
Global biotech company Incyte (INCY) announced on Friday that it has initiated a Phase 3 clinical trial in collaboration with Novartis (NVS) to …
In its report published Monday, Oppenheimer analyst Christopher Marai has boosted the price target of Incyte Corporation (NASDAQ:INCY) stock to $89 (from $75), following the company’s …
In a research report sent to investors today, J.P.
